L-AP4 monohydrate

L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs , with EC 50 s of 0.13, 0.29, 1.0, 249 μM for mGlu 4 , mGlu 8 , mGlu 6 and mGlu 7 receptors, respectively In Vivo L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction. Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats. Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rats.Dosage: 5-30 μg. Administration: Intrathecal inhection 4-5 days. Result: Dose-dependently increased paw withdrawal threshold. Form:Solid IC50& Target:mGlu 4 0.13 μM (EC 50 ) mGlu8 0.29 μM (EC 50 ) mGlu 6 1.0 μM (EC 50 ) mGlu7 249 μM (EC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet